Guggenheim downgraded Boundless Bio from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2024 | Buy → Neutral | Guggenheim |
Guggenheim downgraded Boundless Bio from Buy to Neutral
4 - Boundless Bio, Inc. (0001782303) (Issuer)
4 - Boundless Bio, Inc. (0001782303) (Issuer)
4 - Boundless Bio, Inc. (0001782303) (Issuer)
SC 13D - Boundless Bio, Inc. (0001782303) (Subject)
Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program advancing, with plans for development candidate nomination by mid-2025 Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to pa
SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Piper Sandler's 36th Annual Healthcare Conference. A fireside chat session is scheduled for Wednesday, December 4, 2024, in New York, NY, at 3:30 p.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website and can be accessed via this link: htt
Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept data expected in the second half of 2025 Cash position of $167 million, with operating runway into the fourth quarter of 2026 SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates and reported financial results for the third quarter of 2024. "The third quarter was marked by steady execution across the portfolio, with the POTENTIATE and STAR
8-K - Boundless Bio, Inc. (0001782303) (Filer)
10-Q - Boundless Bio, Inc. (0001782303) (Filer)
8-K - Boundless Bio, Inc. (0001782303) (Filer)